Translartion. Region: Russians Fedetion –
Source: Novosibirsk State University – Novosibirsk State University –
Researchers from Novosibirsk State University, together with colleagues from the Novosibirsk Institute of Organic Chemistry SB RAS, as well as Ireland, have proven the presence of high anti-cancer activity in a chemical compound that includes cationic antimicrobial peptides (AMP), they are also called host defense peptides. In the future, this compound may become the basis for creating a new effective antitumor drug.
— This work took quite a long time, three or four years. But as a result, we managed to demonstrate high activity of the compounds on tumor cell cultures. And, in addition, we were able to study the mechanisms of its action at the molecular level — today this is a mandatory condition for registering any new anti-cancer drug at the global level, — said Andrey Pokrovsky, Head of the Department of Fundamental Medicine, Faculty of Medicine and Psychology, NSU, Corresponding Member of the Russian Academy of Sciences.
The World Health Organization (WHO) has recognized cancer as the second leading cause of death worldwide, with the number of diagnosed cases increasing each year. Chemotherapy remains the mainstay of cancer treatment, but the ability of cancer cells to evade drugs through a number of mechanisms is a major hurdle in therapy.
This, as well as the rather serious side effects inherent in a number of drugs used in chemotherapy, is one of the main reasons for the active search for new methods of treating the disease. And one of the promising areas here is peptide therapy.
Previously, the combination of AMP with a bioactive molecule showed good results in the creation of antimicrobial drugs. It was also found that some peptides specifically recognize and bind to membrane proteins of tumor cells, exerting an antitumor effect. It was this property that the Novosibirsk scientists used in their study.
— As a result, the obtained compound provided targeted delivery to cancer cells of one agent causing DNA damage and a second agent preventing reparation. Thus, it is possible to achieve programmed cell death in tumor tissues. It is clear that at this stage we are not talking about a medicine; for this, the compound needs to go through a long path of preclinical and clinical trials, but this part of the work is beyond the competence and capabilities of the team that conducted this study, — noted Andrey Pokrovsky.
Interest in such compounds among Russian manufacturers is not very high yet – currently in our country the production of pharmaceuticals whose action is based on peptides is practically not developed. But on a global scale this direction is developing rapidly, and the presence of relevant competencies and experience in carrying out such research projects among NSU employees can be considered work for the future.
Please note: This information is raw content directly from the source of the information. It is exactly what the source states and does not reflect the position of MIL-OSI or its clients.